Evidence map›Paper›PMID 25139469›Full record

Trial reportBiometrics2014

Covariate measurement error correction methods in mediation analysis with failure time data.

Shanshan Zhao, Ross L Prentice

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Biometrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Correcting for bias due to mismeasured exposure in mediation analysis with a survival outcome.Journal of the Royal Statistical Society. Series C, Applied statistics · 2025
    Article
  4. Article
  5. A Review of High-Dimensional Mediation Analyses in DNA Methylation Studies.Methods in molecular biology (Clifton, N.J.) · 2022
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Shanshan ZhaoPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, U.S.A.
Ross L Prentice

Funding

Use of Biomarkers in Diagnosis, Prognosis, Risk Prediction and Early Detection ofP01CA053996 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRENTICE, ROSS L · 1991 to 2015
$9.4M
One-carbon metabolism biomarkers and lung cancer riskU01CA155340 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI BRENNAN, PAUL JOSEPH · 2011 to 2015
$4.9M
Cardiovascular Disease Biomarkers and Mediation of Hormone Therapy EffectsR21HL109527 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRENTICE, ROSS L · 2011 to 2012
$484k
NCI NIH HHS CA155340NCI NIH HHS CA53996NCI NIH HHS P01 CA053996NCI NIH HHS U01 CA155340NHLBI NIH HHS HL109527NHLBI NIH HHS R21 HL109527
6 · The paper itself

Abstract

Mediation analysis is important for understanding the mechanisms whereby one variable causes changes in another. Measurement error could obscure the ability of the potential mediator to explain such changes. This article focuses on developing correction methods for measurement error in the mediator with failure time outcomes. We consider a broad definition of measurement error, including technical error, and error associated with temporal variation. The underlying model with the "true" mediator is assumed to be of the Cox proportional hazards model form. The induced hazard ratio for the observed mediator no longer has a simple form independent of the baseline hazard function, due to the conditioning event. We propose a mean-variance regression calibration approach and a follow-up time regression calibration approach, to approximate the partial likelihood for the induced hazard function. Both methods demonstrate value in assessing mediation effects in simulation studies. These methods are generalized to multiple biomarkers and to both case-cohort and nested case-control sampling designs. We apply these correction methods to the Women's Health Initiative hormone therapy trials to understand the mediation effect of several serum sex hormone measures on the relationship between postmenopausal hormone therapy and breast cancer risk.

Indexed as

AlgorithmsArtifactsProportional Hazards ModelsBreast NeoplasmsFemaleHormone Replacement TherapyHumansIncidencePostmenopausePrognosisReproducibility of ResultsRisk AssessmentSensitivity and SpecificityTreatment OutcomeCox modelMean-variance estimating functionsMeasurement errorMediation analysisRegression calibration

Identifiers

PMID25139469
PMCPMC4276494

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.